Novo Nordisk A/S (NVO): Price and Financial Metrics


Novo Nordisk A/S (NVO)

Today's Latest Price: $69.17 USD

0.11 (0.16%)

Updated Sep 28 7:00pm

Add NVO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

NVO Stock Summary

  • With a market capitalization of $162,836,574,000, Novo Nordisk A S has a greater market value than 99.12% of US stocks.
  • Novo Nordisk A S's stock had its IPO on January 1, 1986, making it an older stock than 92.87% of US equities in our set.
  • The volatility of Novo Nordisk A S's share price is greater than that of only 1.31% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Novo Nordisk A S are AZN, TMO, DHR, MDT, and AMGN.
  • NVO's SEC filings can be seen here. And to visit Novo Nordisk A S's official web site, go to www.novonordisk.com.
NVO Daily Price Range
NVO 52-Week Price Range

NVO Stock Price Chart Technical Analysis Charts


NVO Price/Volume Stats

Current price $69.17 52-week high $70.18
Prev. close $69.06 52-week low $49.24
Day low $68.70 Volume 723,861
Day high $69.38 Avg. volume 1,549,056
50-day MA $66.73 Dividend yield 1.07%
200-day MA $62.95 Market Cap 162.88B

Novo Nordisk A/S (NVO) Company Bio


Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The company was founded in 1925 and is based in Bagsvaerd, Denmark.

NVO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$69.17$256.54 271%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Novo Nordisk A S. To summarize, we found that Novo Nordisk A S ranked in the 71th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 273.17%. As for the metrics that stood out in our discounted cash flow analysis of Novo Nordisk A S, consider:

  • The company has produced more trailing twelve month cash flow than 99.07% of its sector Healthcare.
  • The business' balance sheet suggests that 0% of the company's capital is sourced from debt; this is greater than merely 3.3% of the free cash flow producing stocks we're observing.
  • NVO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 57.3% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%264%
1%268%
2%271%
3%275%
4%279%
5%282%

Want more companies with a valuation profile/forecast similar to that of Novo Nordisk A S? See ADUS, LCI, CRHM, SGRY, and ARA.


NVO Latest News Stream


Event/Time News Detail
Loading, please wait...

NVO Latest Social Stream


Loading social stream, please wait...

View Full NVO Social Stream

Latest NVO News From Around the Web

Below are the latest news stories about Novo Nordisk A S that investors may wish to consider to help them evaluate NVO as an investment opportunity.

World’s largest study of cardiovascular disease in type 2 diabetes shows need for improved knowledge and disease management

Bagsværd, Denmark, 24 September 2020 – Novo Nordisk today announced the results of the CAPTURE study, a global non-interventional study to uncover the prevalence of cardiovascular disease and risk and its management in people living with type 2 diabetes. The study, the first of its kind and involving nearly 10,000 participants from 13 countries across five continents, showed that 1 in 3 people with type 2 diabetes have established cardiovascular disease, and 9 in 10 of these had atherosclerotic cardiovascular disease. Atherosclerotic cardiovascular disease is caused by the build-up of fats, cholesterol and other substances in and on the artery walls, which narrows the vessels and results in reduced blood flow, potentially leading to events like heart attack and stroke. CAPTURE also high...

Yahoo | September 24, 2020

LETTER: Local legislators vote again on insulin cap bill

To the Editor: Are you diabetic? Or do you happen to have friend or family member who has been diagnosed with diabetes? If so, you know how critical it is to have access to the wonder drug insulin. Because access to insulin can literally mean the difference between life and death, the Illinois State Legislature recently mandated a cap on the cost of insulin at $100 per 30-day supply. The Governor signed it into law and now Illinois residents are protected from price gouging on this critical medication. You would think that every single state legislator would have voted yes on this bill. And you would almost be right. It passed with strong support from both Democrats and Republicans. Our local Republican State Rep. Tom Demmer, voted no and our local Republican State Sen. Brian Stewart di...

Sauk Valley Media | September 22, 2020

Switching to investigational once-weekly insulin icodec from other basal insulins demonstrated to be efficacious and well-tolerated for people with type 2 diabetes in phase 2 trial

Bagsværd, Denmark, 22 September 2020 – Today, Novo Nordisk announced results from three phase 2 clinical trials for insulin icodec, an investigational once-weekly basal insulin analogue, which were presented during the 56th European Association for the Study of Diabetes (EASD) Annual Meeting 2020. The first showed that switching to insulin icodec from other basal insulins using two different switch approaches was efficacious and well-tolerated compared to once-daily insulin glargine U100 and the switching approaches were without an increased risk of clinically significant or severe hypoglycaemic episodes compared to once-daily insulin glargine U100.1 This 16-week phase 2 clinical trial involved 154 adults with type 2 diabetes inadequately controlled with oral antidiabetic drugs and onc...

Yahoo | September 22, 2020

The Zacks Analyst Blog Highlights: JPM, PYPL, NVO, RHHBY and TM

The Zacks Analyst Blog Highlights: JPM, PYPL, NVO, RHHBY and TM

Yahoo | September 21, 2020

Novo Nordisk insulin production line launches in Iran

Denmark’s Novo Nordisk has created an insulin production line in Iran, Mehr News Agency reported on August 31.Iran’s pharmaceutical industry …

IntelliNews | September 1, 2020

Read More 'NVO' Stories Here

NVO Price Returns

1-mo 5.07%
3-mo 6.22%
6-mo 16.41%
1-year 36.06%
3-year 51.20%
5-year 39.87%
YTD 21.37%
2019 27.79%
2018 -12.54%
2017 52.92%
2016 -37.03%
2015 39.39%

NVO Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full NVO Dividend History

Continue Researching NVO

Want to see what other sources are saying about Novo Nordisk A S's financials and stock price? Try the links below:

Novo Nordisk A S (NVO) Stock Price | Nasdaq
Novo Nordisk A S (NVO) Stock Quote, History and News - Yahoo Finance
Novo Nordisk A S (NVO) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0172 seconds.